Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

8.65USD
24 Feb 2017
Change (% chg)

$-0.10 (-1.14%)
Prev Close
$8.75
Open
$8.70
Day's High
$8.80
Day's Low
$8.55
Volume
39,183
Avg. Vol
57,888
52-wk High
$15.83
52-wk Low
$3.45

NERV.OQ

Chart for NERV.OQ

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio include MIN-101 for the treatment of schizophrenia... (more)

Overall

Beta: --
Market Cap(Mil.): $304.56
Shares Outstanding(Mil.): 34.81
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -1.06 -- --
ROI: -27.63 -3.18 12.94
ROE: -34.14 5.86 14.09

BRIEF-Minerva Neurosciences Q3 loss per share $0.24

* Minerva Neurosciences - intend to meet with FDA to determine late stage clinical strategy, specifically design of next clinical trials with MIN-101

Nov 03 2016

BRIEF-Minerva Neurosciences posts positive data on schizophrenia drug

* Minerva neurosciences announces positive data from six-month extension of phase iib trial of min-101 monotherapy in schizophrenia

Oct 26 2016

BRIEF-Minerva Neurosciences announces positive data from six-month extension of phase IIB trial of min-101 monotherapy in schizophrenia

* Minerva Neurosciences announces positive data from six-month extension of phase IIB trial of min-101 monotherapy in schizophrenia

Oct 26 2016

BRIEF-Minerva Neurosciences provides update on clinical programs

* Statistically significant benefit of MIN-101 was also demonstrated in multiple secondary endpoints Source text for Eikon: Further company coverage:

Sep 26 2016

More From Around the Web

Earnings vs. Estimates